US
US Direct-to-Consumer Genetic Testing Market Industry Trends and Forecast to 2034: Segmented by (Test, Channel, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
US · 2024–2034 · estimates
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
US (this report) at $891.5 Mn.
Canada at 12.2% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$1.19 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $811.2 Mn | — | — |
| 2025 (base) | $891.5 Mn | +$80.3 Mn | — |
| 2026 (forecast) | $979.7 Mn | +$88.3 Mn | +9.9% |
| 2027 (forecast) | $1.08 Bn | +$97.0 Mn | +20.8% |
| 2028 (forecast) | $1.18 Bn | +$106.6 Mn | +32.7% |
| 2029 (forecast) | $1.30 Bn | +$117.1 Mn | +45.9% |
| 2030 (forecast) | $1.43 Bn | +$128.7 Mn | +60.3% |
| 2031 (forecast) | $1.57 Bn | +$141.5 Mn | +76.2% |
| 2032 (forecast) | $1.73 Bn | +$155.5 Mn | +93.6% |
| 2033 (forecast) | $1.90 Bn | +$170.9 Mn | +112.8% |
| 2034 (forecast) | $2.08 Bn | +$187.8 Mn | +133.9% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US (this report)
$891.5 Mn
China
$210.6 Mn
Canada
$196.9 Mn
Japan
$142.5 Mn
Germany
$96.0 Mn
France
$72.4 Mn
Brazil
$72.3 Mn
UK
$64.0 Mn
Italy
$64.6 Mn
Spain
$48.0 Mn
India
$51.2 Mn
Ecuador
$45.9 Mn
Saudi Arabia
$46.3 Mn
Mexico
$39.5 Mn
Australia
$29.5 Mn
New Zealand
$28.6 Mn
Russia
$24.2 Mn
South Africa
$16.8 Mn
UAE
$13.5 Mn
Egypt
$6.7 Mn
Philippines
$4.9 Mn
Hong Kong
$4.7 Mn
Malaysia
$4.0 Mn
Thailand
$2.8 Mn
Singapore
$2.6 Mn
Kenya
$2.0 Mn
Direct-to-consumer genetic tests are bought online by individuals to learn about ancestry, traits and some health risks from a saliva sample.
Key segments of the direct-to-Consumer Genetic Testing market include test (Ancestry, Health Risk and Carrier Status) and channel (Online and Retail).
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the direct-to-Consumer Genetic Testing market.
Routine use of genomics in screening, pharmacy and primary care gives the direct-to-Consumer Genetic Testing market large room to grow.
Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the direct-to-Consumer Genetic Testing market.
The direct-to-Consumer Genetic Testing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for direct-to-Consumer Genetic Testing. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.
What doctors and scientists are doing in Direct-to-Consumer Genetic Testing right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
US · 1 shared keyword
US · 1 shared keyword
US
US
US
US
Digital Health · US
Healthcare Services · US
Healthcare Services · US
Medical Devices · US
Digital Health · US
Medical Devices · US